We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

April 6, 2023

Is There a Space for Digital Health in the World of RNA Based Therapeutics?

Laura Ardill

In this blog we analyse the current landscape of RNA therapeutics and postulate on where best digital health may support this innovative area of medicine.

What are RNA based therapeutics?

It may sound trite to claim that we’re entering a new era in therapeutics. Across industries, especially in the scientific space, almost every minor announcement is prefaced by a declaration of a significant turning point having been reached, which can dampen the impact of true leaps of innovation. However, though the small molecule still reigns supreme, we have witnessed some incredible advances in recent years in the study of other treatment modalities. This is critical at current as available small molecules and antibody therapies can only target around 0.05% of the human genome. A central issue with these existing therapies is that most of them are too large to enter our cells and thus they can only be applied to secreted or extracellular proteins. As a result, many diseases either have a below optimal therapy or no therapy at all due to the inaccessibility of key pathways and processes within our cells involved in their presentation.

Once believed to simply act as a genetic messenger, RNA has since been found to be involved in a plethora of processes within the cell; including activating or deactivating genes, transporting amino acids to their needed sites, and assisting in chemical reactions. Rather than addressing symptoms of an existing disease state or curing it post-occurrence by binding to a disease-related extracellular target, RNA therapies have the potential to alter our genetic and protein make-up at source, and edit out the causing factors that lead to that condition in the first instance. Indeed, the original discovery of the treatment potential of RNA, specifically of using RNA to silence certain genes through interference (“iRNA”), earned Andrew Fire and Craig Mello the Nobel Prize in 2006. 

Since this breakthrough, multiple companies such as well-known industry behemoths Pfizer and Moderna, and more specialised players like Ionis, Arrowhead and Alnylam Pharmaceuticals have developed RNA based pipelines. Many formats of RNA are currently being examined for their potential in human health and disease. 

What do these treatments look like in practice?

RNA therapies have received global attention recently due to the fact that some of the Covid-19 vaccines belong to this technology area. Pfizer/BioNTech and Moderna were the first companies to have mRNA vaccines reach the market for any indication worldwide. Beyond vaccines, there are only a handful of FDA approved RNA therapies in existence at present, with many of them currently in clinical trials. They are aimed at various disease states, including many rare diseases, such as Duchenne Muscular Dystrophy and Primary hyperoxaluria type 1 (PH1), and also more common disease states such as Cystic Fibrosis, Atherosclerotic Cardiovascular disease and Prostate Cancer. Two notable milestones were the FDA’s approval of Sarepta’s Exondys 51 to treat Duchenne Muscular Dystrophy (DMD) and of Ionis’ Spinal Muscular Atrophy (SMA) treatment Spinraza, both in 2016.

In terms of modalities, these therapies are delivered in a variety of ways, predominantly intravenously (IV) and subcutaneously (SQ). However, some are delivered through routes such as inhalation (such as Translate Bio’s Cystic Fibrosis treatment) and through implantation (Silenseed’s Pancreatic Cancer treatment). Depending on the treatment, patients may either need just one dose or, usually in the case of chronic conditions, a treatment course with multiple injections or a continuous infusion (for example for certain types of cancer or genetic disorders).  

Where do digital health solutions fit in?

As digital health continues to search for a stable foothold in current healthcare markets, a new cohort of therapies potentially brings a fresh realm of possibilities. It is worth mentioning that due to the fact that RNA therapies are predominantly administered in a manner that requires a healthcare professional (e.g. via IV), it is unlikely that solutions such as patient adherence or motivation products will have broad applicability in this area. That being said, there may be a few RNA treatments that patients can self-administer; as mentioned, many of these products are in the pipeline and so their exact treatment regimes are yet to be fully realised. For those, medication tracking and adherence companions may be of great help, especially those in the injectables space such as smart disposal bins, injection site tracking or dosing aids. Otherwise, there is the potential for good traction by digital health for:

These areas of opportunity stem from the currently known side effects of some long term RNA based treatments. These include dyspnea, muscle spasms, upper respiratory tract infections, serum creatinine increases, fatigue, abdominal pain and arthralgia, among others. Depending on how ill the patient is at the commencement of treatment, these issues could negatively impact quality of life, or even pose serious risk to their well-being. Tools that aid in monitoring certain symptoms and communicating back with a patient's care team if any of them reach a worrying threshold while they are between doses would be extremely beneficial. Further, RNA therapies can affect liver function, leading to numerous issues such as deficits in certain vitamins. In order for patients to be able to stay well, it would be beneficial for them to be able to measure and track certain indicators from their blood and urine between doses. Finally, as there may be long intervals between dosing sessions with a specialist, tools such as telehealth that can connect key stakeholders in the patient’s journey to each other, and aid in information sharing, would go a long way in ensuring that the treatment journey is as smooth as possible for the patient.

Will We See RNA Focused Digital Health Products Soon?

RNA therapies are relatively new and not much research has been conducted on long term treatment regimes or the lasting effects of being on such technologies; it will be interesting to see how they continue to evolve over the coming years. 

Further, though there are many prominent remote patient monitoring, at-home testing and telehealth solutions on the market; it was difficult at the time of writing to pinpoint any marketed specifically for RNA treatment, or having made a mention of it as a therapeutic area covered. We also could not locate any specific patient education or support resources specifically for those either on RNA therapies, or considering them. Therefore, there may be an opportunity toward developing awareness and education around RNA therapies, and toward considering what specific supports could be put in place for those on such regimes. For platforms that specialise in personalised remote patient monitoring, we will be interested to observe if RNA treatments become more commonly listed modalities covered by them in the near future.

Main image credit: https://claudeai.uk/

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

No upcoming Virtual Events scheduled. Please check back again soon.

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

16TH APRIL 2024 @ 11AM ET

Big Tech and Pharma: Will they, won't they?

As Big Tech seeks to expand their footprint in the health industry, the dynamics of their relationship with Pharma are under scrutiny.

Sophie Ghazal
Sophie Ghazal
Global Digital Solutions and Strategic Alliances, Merck
18th April 2024 @ 11am ET

BYOD: What's your Wearable of Choice?

Wearables, like smartwatches and fitness trackers, have transformed patient health monitoring, providing real-time data for personalised care.

Ralph Morales III
Ralph Morales III
Director, Healthcare Innovation, Oura
23RD APRIL 2024 @ 11AM ET

Masterclass: Digital Health Regulatory Updates

The digital health industry is revolutionising healthcare delivery, but navigating the ever-changing regulatory landscape can be daunting.

Piotr Sokolowski
Piotr Sokolowski
Head of Strategy, MedTech Solutions at S3 Connected Health

HealthXL Insider Boston

Join HealthXL on the 23rd of April in Boston as we discuss the History of Digital Health: Learning from our Mistakes to Succeed in 2024.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.